Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 7 (2010), Issue 4 (April)

1. Effect of dutasteride on the risk of prostate cancer.
   N Engl J Med, 362(13): 1192-202. [Abstract] [Full-text]
2. Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E.
   Oncogene, 29(13): 1883-96. [Abstract] [Full-text]
3. Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines.
   Prostate, 70(6): 675-88. [Abstract] [Full-text]
4. Molecular characterization of the Ggamma-globin-Tag transgenic mouse model of hormone refractory prostate cancer: comparison to human prostate cancer.
   Prostate, 70(6): 630-45. [Abstract] [Full-text]
5. Telomerase enzyme inhibition (TEI) and cytolytic therapy in the management of androgen independent osseous metastatic prostate cancer.
   Prostate, 70(6): 616-29. [Abstract] [Full-text]
6. Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma.
   Prostate, 70(6): 646-53. [Abstract] [Full-text]
7. POU5F1P1, a putative cancer susceptibility gene, is overexpressed in prostatic carcinoma.
   Prostate, 70(6): 666-74. [Abstract] [Full-text]
8. HNF1B and JAZF1 genes, diabetes, and prostate cancer risk.
   Prostate, 70(6): 601-7. [Abstract] [Full-text]
9. Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model.
   Prostate, 70(6): 591-600. [Abstract] [Full-text]
10. Downmodulation of Bcl-2 sensitizes metastatic LNCaP-LN3 cells to undergo apoptosis via the intrinsic pathway.
    Prostate, 70(6): 571-83. [Abstract] [Full-text]
11. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC).
    J Med Chem, 53(7): 2779-96. [Abstract] [Full-text]
12. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.
    Cancer Immunol Immunother, 59(6): 943-53. [Abstract] [Full-text]
13. Increased potency of the PHSCN dendrimer as an inhibitor of human prostate cancer cell invasion, extravasation, and lung colony formation.
    Clin Exp Metastasis, 27(3): 173-84. [Abstract] [Full-text]
14. MicroRNA145 targets BNIP3 and suppresses prostate cancer progression.
    Cancer Res, 70(7): 2728-38. [Abstract] [Full-text]
15. Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer.
    Cancer Res, 70(7): 2809-18. [Abstract] [Full-text]
16. Downregulation of human DAB2IP gene expression in prostate cancer cells results in resistance to ionizing radiation.
    Cancer Res, 70(7): 2829-39. [Abstract] [Full-text]
17. Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells.
    Cancer Res, 70(7): 2613-23. [Abstract] [Full-text]
18. Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance.
    Cancer Res, 70(7): 2595-603. [Abstract] [Full-text]
19. A NADPH oxidase-dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells.
    Cancer Res, 70(7): 2880-90. [Abstract] [Full-text]
20. Implications of body mass index in Japanese patients with prostate cancer who had undergone radical prostatectomy.
    Jpn J Clin Oncol, 40(4): 353-9. [Abstract] [Full-text]
21. Extraperitoneal approach induces postoperative inguinal hernia compared with transperitoneal approach after laparoscopic radical prostatectomy.
    Jpn J Clin Oncol, 40(4): 349-52. [Abstract] [Full-text]
22. Clinical safety and feasibility of a newly developed, simple algorithm for decision-making on neurovascular bundle preservation in radical prostatectomy.
    Jpn J Clin Oncol, 40(4): 343-8. [Abstract] [Full-text]
23. Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growth.
    Biochem Biophys Res Commun, 394(2): 297-302. [Abstract] [Full-text]
24. MK591, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells: synergistic action with LY294002, an inhibitor of phosphatidylinositol 3'-kinase.
    Cancer Lett, 291(2): 167-76. [Abstract] [Full-text]
25. DNA mismatch repair and the transition to hormone independence in breast and prostate cancer.
    Cancer Lett, 291(2): 142-9. [Abstract] [Full-text]
26. Magnetic resonance spectroscopic imaging (1H-MRSI) and dynamic contrast-enhanced magnetic resonance (DCE-MRI): pattern changes from inflammation to prostate cancer.
    Cancer Invest, 28(4): 424-32. [Abstract] [Full-text]
27. DNA repair gene X-ray repair cross-complementing group 1 and xeroderma pigmentosum group D polymorphisms and risk of prostate cancer: a study from North India.
    DNA Cell Biol, 29(4): 183-90. [Abstract] [Full-text]
28. A volumetric trend analysis of the prostate and seminal vesicles during a course of intensity-modulated radiation therapy.
    Am J Clin Oncol, 33(2): 173-5. [Abstract] [Full-text]
29. Optimal equations for describing the relationship between prostate volume, number of sources, and total activity in permanent prostate brachytherapy.
    Am J Clin Oncol, 33(2): 164-7. [Abstract] [Full-text]
30. Prostate cancer modality time trend analyses from 1973 to 2004: a Surveillance, Epidemiology, and End Results registry analysis.
    Am J Clin Oncol, 33(2): 168-72. [Abstract] [Full-text]
31. Androgen depletion up-regulates cadherin-11 expression in prostate cancer.
    J Pathol, 221(1): 68-76. [Abstract] [Full-text]
32. Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase.
    Oncogene, 29(14): 2036-46. [Abstract] [Full-text]
33. Prostaglandin E2 modulates components of the Wnt signaling system in bone and prostate cancer cells.
    Biochem Biophys Res Commun, 394(3): 715-20. [Abstract] [Full-text]
34. Ingestion of selenium and other antioxidants during prostate cancer radiotherapy: a good thing?
    Cancer Treat Rev, 36(3): 230-4. [Abstract] [Full-text]
35. Risk stratification of men choosing surveillance for low risk prostate cancer.
    J Urol, 183(5): 1779-85. [Abstract] [Full-text]
36. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
    J Urol, 183(5): 2054-61. [Abstract] [Full-text]
37. Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells.
    J Urol, 183(5): 2045-53. [Abstract] [Full-text]
38. The EGFR polymorphism rs884419 is associated with freedom from recurrence in patients with resected prostate cancer.
    J Urol, 183(5): 2062-9. [Abstract] [Full-text]
39. Preoperative prostate specific antigen doubling time is not a useful predictor of biochemical progression after radical prostatectomy.
    J Urol, 183(5): 1816-21. [Abstract] [Full-text]
40. Tumor volume in radical prostatectomy specimens assessed by digital image analysis software correlates with other prognostic factors.
    J Urol, 183(5): 1808-14. [Abstract] [Full-text]
41. Quality of life after open or robotic prostatectomy, cryoablation or brachytherapy for localized prostate cancer.
    J Urol, 183(5): 1822-8. [Abstract] [Full-text]
42. Do anxiety and distress increase during active surveillance for low risk prostate cancer?
    J Urol, 183(5): 1786-91. [Abstract] [Full-text]
43. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity.
    J Urol, 183(5): 1792-6. [Abstract] [Full-text]
44. Robotic radical prostatectomy for elderly patients: probability of achieving continence and potency 1 year after surgery.
    J Urol, 183(5): 1803-7. [Abstract] [Full-text]
45. Prostate cancer screening in men 75 years old or older: an assessment of self-reported health status and life expectancy.
    J Urol, 183(5): 1798-802. [Abstract] [Full-text]
46. Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer.
    J Urol, 183(5): 1751-6. [Abstract] [Full-text]
47. Inhibition of calcium-independent phospholipase A2 activates p38 MAPK signaling pathways during cytostasis in prostate cancer cells.
    Biochem Pharmacol, 79(12): 1727-35. [Abstract] [Full-text]
48. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading.
    Cancer Cell, 17(4): 319-32. [Abstract] [Full-text]
49. Prostate cancer: beta control your hormones.
    Cancer Cell, 17(4): 311-2. [Abstract] [Full-text]
50. alpha-Tocopheryl succinate promotes selective cell death induced by vitamin K3 in combination with ascorbate.
    Br J Cancer, 102(8): 1224-34. [Abstract] [Full-text]
51. Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy.
    Strahlenther Onkol, 186(4): 197-202. [Abstract] [Full-text]
52. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.
    Cancer Chemother Pharmacol, 66(1): 181-9. [Abstract] [Full-text]
53. Sex or survival: short-term versus long-term androgen deprivation in patients with locally advanced prostate cancer treated with radiotherapy.
    Cancer, 116(8): 1909-17. [Abstract] [Full-text]
54. Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death.
    Cancer, 116(8): 1887-92. [Abstract] [Full-text]
55. Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer.
    Cancer Res, 70(8): 3382-90. [Abstract] [Full-text]
56. NKX3.1 activates cellular response to DNA damage.
    Cancer Res, 70(8): 3089-97. [Abstract] [Full-text]
57. Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells.
    Cancer Res, 70(8): 3309-19. [Abstract] [Full-text]
58. ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21.
    Cancer Res, 70(8): 3239-48. [Abstract] [Full-text]
59. Immunohistochemical expression of BRCA1 and lethal prostate cancer.
    Cancer Res, 70(8): 3136-9. [Abstract] [Full-text]
60. p66Shc is indispensable for phenethyl isothiocyanate-induced apoptosis in human prostate cancer cells.
    Cancer Res, 70(8): 3150-8. [Abstract] [Full-text]
61. Relating dose outside the prostate with freedom from failure in the Dutch trial 68 Gy vs. 78 Gy.
    Int J Radiat Oncol Biol Phys, 77(1): 131-8. [Abstract] [Full-text]
62. Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate cancer.
    Int J Radiat Oncol Biol Phys, 77(1): 139-46. [Abstract] [Full-text]
63. Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography.
    Int J Radiat Oncol Biol Phys, 77(1): 160-4. [Abstract] [Full-text]
64. Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy.
    Int J Radiat Oncol Biol Phys, 77(1): 147-52. [Abstract] [Full-text]
65. Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy.
    Int J Radiat Oncol Biol Phys, 77(1): 125-30. [Abstract] [Full-text]
66. A prospective study of intrafraction prostate motion in the prone vs. supine position.
    Int J Radiat Oncol Biol Phys, 77(1): 165-70. [Abstract] [Full-text]
67. Dose escalation to the dominant intraprostatic lesion defined by sextant biopsy in a permanent prostate I-125 implant: a prospective comparative toxicity analysis.
    Int J Radiat Oncol Biol Phys, 77(1): 153-9. [Abstract] [Full-text]
68. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
    J Clin Oncol, 28(12): 2070-6. [Abstract] [Full-text]
69. PIM-1 gene RNA interference induces growth inhibition and apoptosis of prostate cancer cells and suppresses tumor progression in vivo.
    J Surg Oncol, 101(6): 513-9. [Abstract] [Full-text]
70. A method to separate the rectum from the prostate during proton beam radiotherapy of prostate cancer patients.
    Acta Oncol, 49(4): 500-5. [Abstract] [Full-text]
71. Variation in position and volume of organs at risk in the small pelvis.
    Acta Oncol, 49(4): 491-9. [Abstract] [Full-text]
72. Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts.
    Int J Cancer, 126(12): 2826-34. [Abstract] [Full-text]
73. Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics using novel sumLINK and sumLOD analyses.
    Prostate, 70(7): 735-44. [Abstract] [Full-text]
74. The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy.
    Prostate, 70(7): 718-26. [Abstract] [Full-text]
75. Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice.
    Prostate, 70(7): 788-96. [Abstract] [Full-text]
76. Racial differences in prostate cancer risk remain among US servicemen with equal access to care.
    Prostate, 70(7): 727-34. [Abstract] [Full-text]
77. Retrospective analysis of prostate cancer recurrence potential with tissue metabolomic profiles.
    Prostate, 70(7): 710-7. [Abstract] [Full-text]
78. Controversies in the treatment of high-risk prostate cancer--what is the optimal combination of hormonal therapy and radiotherapy: a review of literature.
    Prostate, 70(7): 701-9. [Abstract] [Full-text]
79. Induction of neuronal apoptosis inhibitory protein expression in response to androgen deprivation in prostate cancer.
    Cancer Lett, 292(2): 176-85. [Abstract] [Full-text]
80. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.
    J Natl Cancer Inst, 102(8): 522-8. [Abstract] [Full-text]
81. Prostate tissue composition and MR measurements: investigating the relationships between ADC, T2, K(trans), v(e), and corresponding histologic features.
    Radiology, 255(2): 485-94. [Abstract] [Full-text]
82. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.
    Lancet, 375(9724): 1437-46. [Abstract] [Full-text]
83. Increased risk of high-grade prostate cancer among infertile men.
    Cancer, 116(9): 2140-7. [Abstract] [Full-text]
84. Quality of end-of-life care in low-income, uninsured men dying of prostate cancer.
    Cancer, 116(9): 2126-31. [Abstract] [Full-text]
85. Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer.
    Cancer, 116(9): 2132-9. [Abstract] [Full-text]
86. The Prostate Cancer Foundation 16th Annual Scientific Retreat: meeting report.
    Prostate, 70(8): 916-20. [Abstract] [Full-text]
87. Androgens, growth factors, and risk of prostate cancer: the Multiethnic Cohort.
    Prostate, 70(8): 906-15. [Abstract] [Full-text]
88. Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity.
    Prostate, 70(8): 883-8. [Abstract] [Full-text]
89. Genetic alterations and changes in expression of histone demethylases in prostate cancer.
    Prostate, 70(8): 889-98. [Abstract] [Full-text]
90. Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer.
    Prostate, 70(8): 875-82. [Abstract] [Full-text]
91. Regulation of androgen receptor transactivity and mTOR-S6 kinase pathway by Rheb in prostate cancer cell proliferation.
    Prostate, 70(8): 866-74. [Abstract] [Full-text]
92. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer.
    Prostate, 70(8): 848-55. [Abstract] [Full-text]
93. Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors.
    Prostate, 70(8): 817-24. [Abstract] [Full-text]
94. Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result.
    Br J Cancer, 102(9): 1335-40. [Abstract] [Full-text]
95. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer.
    Cancer Immunol Immunother, 59(7): 1001-9. [Abstract] [Full-text]
96. Role of multi-hnRNP nuclear complex in regulation of tumor suppressor ANXA7 in prostate cancer cells.
    Oncogene, 29(17): 2457-66. [Abstract] [Full-text]
97. Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma.
    Oncogene, 29(17): 2477-87. [Abstract] [Full-text]
98. Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24.
    Cancer Res, 70(9): 3667-76. [Abstract] [Full-text]
99. In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice.
    Cancer Res, 70(9): 3473-82. [Abstract] [Full-text]
100. Concomitant tumor and minor histocompatibility antigen-specific immunity initiate rejection and maintain remission from established spontaneous solid tumors.
     Cancer Res, 70(9): 3505-14. [Abstract] [Full-text]
101. Beta1 integrins mediate cell proliferation in three-dimensional cultures by regulating expression of the sonic hedgehog effector protein, GLI1.
     J Cell Physiol, 224(1): 210-7. [Abstract] [Full-text]
102. Transcriptional regulation of Rex1 (zfp42) in normal prostate epithelial cells and prostate cancer cells.
     J Cell Physiol, 224(1): 17-27. [Abstract] [Full-text]
103. Changes in bone health and skeletal-related events following implementation of a multidisciplinary consensus statement guiding surveillance and treatment of men undergoing androgen deprivation therapy for prostate cancer.
     Aging Male, 13(2): 120-3. [Abstract] [Full-text]
104. Lipoproteins, sex hormones and inflammatory markers in association with prostate cancer.
     Aging Male, 13(2): 87-92. [Abstract] [Full-text]

© 2004-2012 Prostate Cancer Research Today. All Rights Reserved.